These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 16543688

  • 1. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J, Kanno Y, Suzuki H.
    Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
    [Abstract] [Full Text] [Related]

  • 2. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y, Takenaka T, Nakamura T, Suzuki H.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [Abstract] [Full Text] [Related]

  • 3. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A.
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
    Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, Tatematsu S, Wakino S, Saruta T.
    Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov 04; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
    Abe H, Minatoguchi S, Ohashi H, Murata I, Minagawa T, Okuma T, Yokoyama H, Takatsu H, Takaya T, Nagano T, Osumi Y, Kakami M, Tsukamoto T, Tanaka T, Hiei K, Fujiwara H.
    Hypertens Res; 2007 Oct 04; 30(10):929-35. PubMed ID: 18049024
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec 04; 10(4):195-200. PubMed ID: 20026868
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.